文献速递毛发、甲与色素性疾病

重度抑郁症与斑秃双向关联的评估

Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata.
PubMed 文献 · JAMA Dermatol · 2019-01-01

这项基于英国健康改善网络的人群回顾性队列研究评估了重度抑郁症与斑秃的双向关联。调整协变量后,重度抑郁症使后续发生斑秃的风险增加90%(HR 1.90,95%CI 1.67-2.15,P<.001),抗抑郁药对斑秃风险显示保护作用(HR 0.57,95%CI 0.53-0.62,P<.001);斑秃使后续发生重度抑郁症的风险增加34%(HR 1.34,95%CI 1.23-1.46,P<.001)。

要点

  • 重度抑郁症患者后续发生斑秃的风险增加90%(HR 1.90,95%CI 1.67-2.15,P<.001)。
  • 抗抑郁药使用对斑秃风险显示保护作用(HR 0.57,95%CI 0.53-0.62,P<.001)。
  • 斑秃患者后续发生重度抑郁症的风险增加34%(HR 1.34,95%CI 1.23-1.46,P<.001)。

核心结论

  • 这些时间分析提示,斑秃患者有后续发生重度抑郁症的风险,而重度抑郁症也似乎是斑秃发生的重要危险因素,抗抑郁药使用混杂了该风险。

研究设计与样本

  • 这项基于人群的回顾性队列研究纳入1986年1月1日至2012年5月16日在英国全科诊所注册于健康改善网络、年龄10至90岁的患者。
  • 统计分析于2017年8月17日至2018年4月23日进行。
  • 评估斑秃风险时定义两个队列:新发重度抑郁症诊断患者(暴露)和参考一般人群队列。
  • 评估重度抑郁症风险时定义两个队列:新发斑秃诊断患者(暴露)和参考一般人群队列。
  • 暴露队列的人时被划分为未暴露和暴露时间。

主要发现

  • 在斑秃风险分析中,405339例发生重度抑郁症的患者(263916例女性、141423例男性;中位年龄36.7岁,四分位距26.6-50.5岁)和5738596例未发生重度抑郁症的患者(2912201例女性、2826395例男性;中位年龄35.8岁,四分位距25.3-52.6岁)被随访26年。
  • 调整协变量后,重度抑郁症使后续发生斑秃的风险增加90%(HR 1.90,95%CI 1.67-2.15,P<.001)。
  • 抗抑郁药对斑秃风险显示保护作用(HR 0.57,95%CI 0.53-0.62,P<.001)。
  • 在重度抑郁症风险分析中,6861例发生斑秃的患者(3846例女性、3015例男性;中位年龄31.5岁,四分位距18.2岁)和6137342例未发生斑秃的患者(3172371例女性、2964971例男性;中位年龄35.9岁,四分位距27.0岁)被随访26年。
  • 调整协变量后,斑秃使后续发生重度抑郁症的风险增加34%(HR 1.34,95%CI 1.23-1.46,P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Alopecia areata (AA) is an autoimmune disease characterized by hair loss that can impose a substantial psychological burden on patients, including major depressive disorder (MDD), yet many patients report mental health symptoms prior to the onset of AA. As such, there may be an association between MDD and AA that acts in both directions. OBJECTIVE: To assess the bidirectional association between MDD and AA. DESIGN, SETTING, AND PARTICIPANTS: This population-based retrospective cohort study included patients 10 to 90 years of age registered with The Health Improvement Network in general practices in the United Kingdom between January 1, 1986, and May 16, 2012. Statistical analysis was conducted from August 17, 2017, to April 23, 2018. To assess the risk of AA, the following 2 cohorts were defined: patients with an incident diagnosis of MDD (exposure) and a reference general population cohort. To assess the risk of MDD, the following 2 cohorts were defined: patients with an incident diagnosis of AA (exposure) and a reference general population cohort. Person-time was partitioned into unexposed and exposed time in the exposure cohorts. MAIN OUTCOMES AND MEASURES: In the analysis of the risk of AA, development of incident AA during follow-up was considered the main outcome measure. In the analysis of the risk of MDD, development of incident MDD during follow-up was considered the primary outcome measure. RESULTS: In the analysis of the risk of AA, 405 339 patients who developed MDD (263 916 women and 141 423 men; median age, 36.7 years [interquartile range, 26.6-50.5 years]) and 5 738 596 patients who did not develop MDD (2 912 201 women and 2 826 395 men; median age, 35.8 years [interquartile range, 25.3-52.6 years]) were followed up for 26 years. After adjustment for covariates, MDD was found to increase the risk of subsequently developing AA by 90% (hazard ratio, 1.90; 95% CI, 1.67-2.15; P < .001). Antidepressants demonstrated a protective effect on the risk of AA (hazard ratio, 0.57; 95% CI, 0.53-0.62; P < .001). In the analysis of the risk of MDD, 6861 patients who developed AA (3846 women and 3015 men; median age, 31.5 years [interquartile range, 18.2 years]) and 6 137 342 patients who did not develop AA (3 172 371 women and 2 964 971 men; median age, 35.9 years [interquartile range, 27.0 years]) were followed up for 26 years. After adjustment for covariates, AA was found to increase the risk of subsequently developing MDD by 34% (hazard ratio, 1.34; 95% CI, 1.23-1.46; P < .001). CONCLUSIONS AND RELEVANCE: These temporal analyses suggest that, while patients with AA are at risk for subsequently developing MDD, having MDD also appears to be a significant risk factor for development of AA, with antidepressant use confounding this risk.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Vallerand IA, Lewinson RT, Parsons LM, et al. Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata. JAMA Dermatol. 2019. PMID: 30649133. doi:10.1001/jamadermatol.2018.4398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。